Theralink® signs definitive merger agreement to be acquired by imac holdings, a nasdaq listed company

Theralink's patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict which fda-approved drugs may be effective in each solid tumor cancer golden, colo. , may 23, 2023 /prnewswire/ --  theralink technologies, inc.  (otc: ther) ("theralink") and imac holdings, inc.  (nasdaq: back) ("imac"), today announced that they have entered into a definitive agreement and plan of merger (the "merger agreement") under which theralink will merge with a newly-formed wholly-owned subsidiary of imac in a stock-for-stock reverse merger transaction (the "merger") in which theralink will survive as a wholly-owned subsidiary of imac, a nasdaq-listed company.
BACK Ratings Summary
BACK Quant Ranking